Ampliphi Biosciences Stock Rises 9.3%

Investors Speculate on What's Next for the Biotech Firm

Feb. 26, 2026 at 5:21am

Got story updates? Submit your updates here. ›

Ampliphi Biosciences (NYSEAMERICAN:APHB) saw its stock price increase by 9.3% on Wednesday, trading as high as $9.59 per share. The biopharmaceutical company, headquartered in Cambridge, Massachusetts, is focused on developing novel therapies to combat drug-resistant infections.

Why it matters

Ampliphi Biosciences' stock performance is being closely watched as the company advances its lead product candidate, exeporfinium chloride (XF-73), through late-stage clinical trials. XF-73 is a topical antibacterial designed to decolonize Staphylococcus aureus in patients undergoing high-risk surgical procedures, addressing the growing global threat of antibiotic resistance.

The details

The company's stock traded approximately 133,273 shares during mid-day trading on Wednesday, a decline of 84% from the average daily volume of 842,200 shares. Ampliphi Biosciences has a 50-day moving average of $6.96 and a 200-day moving average of $5.17.

  • Ampliphi Biosciences' stock price increased by 9.3% on Wednesday, February 26, 2026.

The players

Ampliphi Biosciences, Inc.

A clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing novel therapies to prevent and treat life-threatening drug-resistant infections.

Got photos? Submit your photos here. ›

The takeaway

Ampliphi Biosciences' stock performance reflects investor interest in the company's efforts to address the growing global threat of antibiotic resistance through the development of its lead product candidate, XF-73. The company's progress in late-stage clinical trials will be closely watched by the market.